Â鶹´«Ã½¸ßÇå°æ

Dr. Marks is an Associate Professor of Medicine at Â鶹´«Ã½¸ßÇå°æ (WCM) where she conducts clinical trials related to HIV, HCV and COVID prevention and treatment. She received Internal Medicine residency and Infectious Diseases fellowship training at New York-Presbyterian Hospital (Cornell), where she focused clinical training and research on HIV and hepatitis virus infections and completed Weill Cornell's Master's Degree in Clinical Investigation. She has taken a leadership role advancing the treatment of HIV and hepatitis C in underserved populations at Cornell through clinical, education, and research activities. Her current research focuses on improving treatment outcomes in patients with HIV and hepatitis virus co-infections. Several research projects have focused specifically on people who inject drugs including an ongoing R01-funded study comparing HCV treatment delivery at a community syringe exchange program with usual care. She is the co-chair of an AIDS Clinical Trials Group (ACTG) multi-center study to assesses a novel Hepatitis B vaccine, currently serve on three ACTG protocol teams, and is a member of the ACTG Hepatitis Transformative Science Group. She serves as a co-director of the Cornell HIV/AIDS Clinical Trials Unit, where she conducts several treatment studies related to HIV and hepatitis viruses.  She served as co-chair of IDSA/AASLD’s joint guidelines panel for “Recommendations for testing, managing and treating hepatitis C” and as a member of New York State’s HCV guidelines panel. When the COVID pandemic hit New York City, she led the phase 3 studies of remdesivir at Weill Cornell as well as a phase 3 studies of a vaccine for the prevention of COVID.